BMS ponders sales cuts due to Pargluva delay
Facing the reality that diabetes drug Pargluva (muraglitazar) won't be available for near-term promotion, Bristol-Myers Squibb is prepared to reduce its CV-metabolic sales force.
"The size of our current U.S. sales force was scaled to support a portfolio that we believed would be available for promotion," said Lamberto Andreotti, BMS executive vice president, president worldwide pharmaceuticals, during an investor meeting this week.
Pargluva was to be a centerpiece of that portfolio, but the FDA withheld approval in October, saying it needed more data from the company to examine the drug's risk for heart problems.
Cuts could come by early 2006, Andreotti said, if reps cannot be redistributed.
BMS has not stated whether it will pursue marketing approval for Pargluva. The product was not included among other compounds in a pipeline list provided for the investor meeting.